PDCD1 and cancer: It is widely accepted that successful anti-tumor immune responses following PD-1/PD-L1 blockade require tumor-specific T cell reactivation and clonal proliferation in the TME, and the different results of cancer immunotherapy can be partly ascribed to the TME heterogeneity [33, 34].